Sucampo's retinitis pigmentosa candidate given orphan designation in Europe

Sucampo Pharmaceuticals has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa. RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today. A form of unoprostone isopropyl is currently approved in the United States. In addition, the FDA has granted orphan drug designation to unoprostone isopropyl for treatment of RP.